is_manufactured_by has function has role immunizes against disease immunizes recipient immunizes against pathogen has drug brand name Streptococcus pneumonia Streptococcus pneumoniae Homo sapiens FDA licensed vaccine role USA licensed human vaccine polyvalent pneumococcal vaccine preventive vaccine function conjugate vaccine role Pneumococcal 21-valent conjugate vaccine vaccine https://www.fda.gov/media/179426/download?attachment CAPVAXIVE CAPVAXIVE is indicated for: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A,15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B inindividuals 18 years of age and older. Active immunization for the prevention of pneumonia caused by S. pneumoniaeserotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F,23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older. The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 125814 Xingxian Li Jie Zheng CAPVAXIVE PCV21 vaccine multivalent role licensed human streptococcus pneumoniae vaccine capsular polysaccharide vaccine role Streptococcus pneumoniae conjugate vaccine Merck Sharp & Dohme LLC CAPVAXIVE